Double maintains 1 strategies that include ALT - Altimmune, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VOD | -11.96% | $26.57B | +19.32% | 4.46% |
| CNC | -11.48% | $16.22B | -50.41% | 0.00% |
| CIG.C | -11.09% | $2.65B | +23.47% | 0.00% |
| KEP | -9.41% | $17.90B | +91.48% | 0.54% |
| VHC | -9.34% | $57.60M | +131.12% | 0.00% |
| AEP | -8.76% | $55.53B | +18.55% | 3.53% |
| EXC | -8.56% | $43.41B | +24.89% | 3.62% |
| CI | -8.55% | $83.35B | -4.99% | 1.87% |
| TEF | -7.85% | $29.46B | +22.82% | 6.25% |
| CME | -7.31% | $99.33B | +45.14% | 1.75% |
| RLMD | -7.02% | $20.25M | -85.12% | 0.00% |
| PM | -6.91% | $276.62B | +74.80% | 3.02% |
| VSA | -6.80% | $8.76M | -15.57% | 0.00% |
| K | -6.76% | $27.53B | +40.77% | 2.87% |
| NEUE | -6.49% | $60.98M | +32.62% | 0.00% |
| LITB | -5.86% | $23.17M | -74.54% | 0.00% |
| DOGZ | -5.84% | $127.69M | -37.35% | 0.00% |
| DFDV | -5.71% | $298.06M | +2,070.86% | 0.00% |
| STG | -5.66% | $31.09M | -22.74% | 0.00% |
| MVO | -5.48% | $67.62M | -36.43% | 21.27% |
Current Value
$4.591 Year Return
Current Value
$4.591 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 45.31% | $4.90B | 0.35% |
| PBE | 42.38% | $228.63M | 0.58% |
| IBB | 42.35% | $5.44B | 0.45% |
| GNOM | 41.47% | $46.32M | 0.5% |
| FBT | 39.16% | $1.02B | 0.54% |
| BBH | 39.01% | $340.09M | 0.35% |
| ARKG | 38.79% | $1.06B | 0.75% |
| XPH | 37.48% | $150.90M | 0.35% |
| QQQJ | 37.43% | $630.82M | 0.15% |
| PTH | 37.12% | $97.73M | 0.6% |
| IWC | 36.63% | $847.74M | 0.6% |
| DUHP | 36.20% | $8.84B | 0.21% |
| CLOU | 36.15% | $335.57M | 0.68% |
| KRMA | 35.98% | $656.49M | 0.43% |
| IWO | 35.75% | $11.87B | 0.24% |
| VBK | 35.70% | $19.31B | 0.07% |
| TECB | 35.67% | $443.30M | 0.3% |
| EALT | 35.65% | $129.86M | 0.69% |
| HELO | 35.46% | $3.30B | 0.5% |
| SUSA | 35.38% | $3.60B | 0.25% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XNCR | 39.76% | $588.58M | -55.05% | 0.00% |
| CLDX | 39.04% | $1.42B | -42.61% | 0.00% |
| CRNX | 38.87% | $2.75B | -39.10% | 0.00% |
| DNLI | 38.09% | $2.08B | -31.63% | 0.00% |
| VKTX | 36.96% | $3.39B | -44.25% | 0.00% |
| SDGR | 36.41% | $1.57B | +4.44% | 0.00% |
| CDXS | 36.21% | $221.20M | -10.40% | 0.00% |
| EQIX | 35.99% | $75.07B | +0.07% | 2.31% |
| BDTX | 35.94% | $142.16M | -50.10% | 0.00% |
| TREX | 35.88% | $6.29B | -19.61% | 0.00% |
| LSCC | 35.70% | $7.38B | -10.21% | 0.00% |
| SLAB | 35.62% | $4.57B | +22.05% | 0.00% |
| RARE | 35.37% | $3.73B | -6.70% | 0.00% |
| ABUS | 35.25% | $609.06M | -6.47% | 0.00% |
| CRON | 35.23% | $801.67M | -7.14% | 0.00% |
| MEDP | 35.18% | $9.27B | -21.52% | 0.00% |
| XPER | 34.89% | $367.32M | +2.94% | 0.00% |
| CRSP | 34.82% | $4.73B | -0.38% | 0.00% |
| ENTG | 34.48% | $13.17B | -37.94% | 0.46% |
| DYN | 34.23% | $1.16B | -77.45% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -27.24% | $185.99M | 0.85% |
| TAIL | -26.51% | $95.09M | 0.59% |
| BTAL | -22.39% | $312.42M | 1.43% |
| IVOL | -17.92% | $342.02M | 1.02% |
| SPTS | -12.85% | $5.77B | 0.03% |
| FXY | -12.55% | $812.67M | 0.4% |
| XONE | -12.48% | $627.68M | 0.03% |
| STPZ | -11.60% | $443.02M | 0.2% |
| ULST | -10.79% | $595.49M | 0.2% |
| CGSM | -10.36% | $716.04M | 0.25% |
| BILS | -9.93% | $3.80B | 0.1356% |
| PSQA | -9.74% | $36.46M | 0.2% |
| UTWO | -9.52% | $376.38M | 0.15% |
| VTIP | -8.78% | $15.21B | 0.03% |
| XHLF | -8.21% | $1.73B | 0.03% |
| UDN | -7.95% | $147.89M | 0.78% |
| TDTT | -7.93% | $2.62B | 0.18% |
| VGSH | -7.79% | $22.64B | 0.03% |
| IBTJ | -7.24% | $682.49M | 0.07% |
| IEI | -7.05% | $15.58B | 0.15% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FLIA | -0.02% | $708.62M | 0.25% |
| BUXX | 0.10% | $312.37M | 0.25% |
| BIV | -0.12% | $23.21B | 0.03% |
| SCHQ | -0.13% | $773.67M | 0.03% |
| LGOV | -0.17% | $668.41M | 0.67% |
| BIL | -0.21% | $41.97B | 0.1356% |
| VGLT | 0.21% | $9.69B | 0.04% |
| ISTB | -0.22% | $4.41B | 0.06% |
| SPMB | 0.24% | $6.15B | 0.04% |
| BAB | -0.33% | $928.83M | 0.28% |
| TOTL | -0.34% | $3.81B | 0.55% |
| OWNS | -0.36% | $128.62M | 0.3% |
| JPST | 0.36% | $31.92B | 0.18% |
| BSMW | 0.37% | $107.54M | 0.18% |
| TIPZ | -0.39% | $94.09M | 0.2% |
| JPLD | -0.42% | $1.78B | 0.24% |
| TLH | 0.44% | $11.35B | 0.15% |
| UITB | 0.44% | $2.34B | 0.39% |
| SPTL | 0.45% | $11.25B | 0.03% |
| SPIP | 0.58% | $954.85M | 0.12% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CNX | 0.02% | $4.69B | +27.30% | 0.00% |
| SAFT | 0.04% | $1.11B | -0.98% | 4.79% |
| NOC | -0.06% | $72.66B | +19.14% | 1.68% |
| NGG | -0.07% | $69.16B | +16.90% | 4.35% |
| TRP | 0.14% | $49.06B | +38.33% | 5.30% |
| KNDI | -0.15% | $98.02M | -41.24% | 0.00% |
| STNG | 0.22% | $2.19B | -45.28% | 3.75% |
| ELV | 0.23% | $78.96B | -33.97% | 1.93% |
| AIFU | 0.25% | $15.34M | +65.63% | 0.00% |
| UNH | 0.25% | $279.13B | -37.47% | 2.81% |
| SHLS | 0.28% | $955.41M | -8.41% | 0.00% |
| WMB | 0.29% | $70.44B | +36.09% | 3.37% |
| IMNN | 0.30% | $14.82M | -45.57% | 0.00% |
| QNRX | 0.35% | $5.13M | -58.29% | 0.00% |
| PPC | -0.38% | $10.85B | +36.15% | 0.00% |
| GLP | 0.51% | $1.77B | +14.81% | 5.67% |
| RLX | -0.59% | $2.07B | +25.27% | 0.44% |
| ZCMD | -0.73% | $30.81M | +2.52% | 0.00% |
| KO | -0.73% | $302.33B | +12.04% | 2.84% |
| ULS | 0.73% | $14.26B | +63.55% | 0.72% |
Yahoo
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in the RESTORE Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol-Associated Liver Disease (ALD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist in development f
Finnhub
Altimmune, Inc. announced that it has enrolled the first patient in the RESTORE Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol-Associated Liver Disease ....
Yahoo
Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive topline results from its Phase 2b IMPACT trial evaluating Pemvidutide, a treatment candidate for metabolic dysfunction-associated steatohepatitis (MASH). The results mark a key milestone in advancing potential therapies for this chronic liver condition. According to the […]
Finnhub
NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. . Such investors are advised to contact Danielle Peyton at...
Finnhub
Altimmune, Inc. dropped from Russell 3000E Value Index...
Finnhub
Altimmune, Inc. dropped from Russell 3000 Value Index...
